Title
Category
Credits
Event date
Cost
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
  • Hepatitis
  • Medical Conditions
  • Neuropsychiatric Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Increased screening for hepatitis C virus among people with serious mental illness is key to achieving global eradication of the virus.
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
  • Cognition
  • Geriatric Psychiatry
  • Primary Care
  • Substance Use Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
When older patients present with cognitive decline, it is important to rule out any organic, mood-related, or substance-induced etiology, such as alcohol use disorder.
  • Eating Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Night eating syndrome is a condition that requires early identification and management, especially among adolescents who develop symptoms during the transition into adulthood.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.
  • Dementia
  • Geriatric Psychiatry
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Dementia-related psychosis (DRP) occurs in all forms of dementia and at all stages. What tactics should be used when talking with patients and their care partners about DRP? How is it best treated?
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Patient/Physician Communication
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
  • Alzheimer Disease
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How do investigational drugs for Alzheimer disease differ from those currently prescribed to patients? Dr Burke shares her insights.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer an overview of best practices for managing early-stage Alzheimer disease as well as a look at the future.

Pages